- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03775928
Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer
Phase Ⅱ Study of Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Triple-negative breast cancer (TNBC) has the characteristics of early onset, high malignancy, less treatment, and resistance to treatment. Advanced patients have shorter survival than other subtypes. Maintenance therapy after combination chemotherapy can prolong the disease control time in patients with advanced TNBC. How to prolong the disease control time of patients with advanced TNBC without affecting the quality of life has become the focus of current research.
Anti-angiogenic drugs are currently one of the few targeted therapies that have achieved some efficacy in TNBC. Apatinib, a targeted inhibitor of VEGF receptor 2 (VEGFR2), shows significant antitumor activity in the patients with breast cancer. The results of this study will help explore the new treatment of small molecule anti-angiogenic drugs for TNBC maintenance therapy, and provide some new ideas for improving individualized treatment options for patients with advanced TNBC.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Binghe Xu
- Phone Number: 861087788120 86-87788826
- Email: xubinghe@medmail.com
Study Contact Backup
- Name: Bo Lan
- Phone Number: 861087788120 86-87788114
- Email: daxiaolanbo@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100021
- Recruiting
- Cancer Hospital, ChineseAMS
-
Contact:
- Binghe Xu, PhD
- Phone Number: 86-10-87788826
- Email: xubinghe@medmail.com
-
Contact:
- Bo Lan, PhD
- Phone Number: 86-10-87788114
- Email: daxiaolanbo@163.com
-
Sub-Investigator:
- Fei Ma, PhD
-
Sub-Investigator:
- Bo Lan, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age:18~75 years;
- Triple-negative breast cancer (TNBC) confirmed by histology examination;
- patients had received first-line combination chemotherapy for advanced metastatic disease, and had a complete response, partial response or stable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria;
- received endocrine therapy for metastatic disease before first-line chemotherapy were allowed;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
- A life expectancy of more than 12 weeks;
- Baseline blood routine examination in accordance with the following criteria : ANC≥1.5×109/L,PLT≥90×109/L,Hb≥90g/L;
Liver and renal function in accordance with the following criteria: total bilirubin less than 1.5 times the upper limit of normal value; aspartate aminotransferase (AST), or alanine aminotransferase (ALT) less than 2.5 times the upper limit of normal value, less than 5 times the upper limit of normal value in patients with liver metastases.
the creatinine clearance rate calculated greater than 60 mL/min;
- Females of childbearing potential must be a pregnancy test in 7 days before participating ( including serum or urine), and the results were negative, and they are willing to take effective contraceptive methods During the trial and within 8 weeks after the last dose;
- Obtain informed consent from patients before starting any research-related operations and treatments to confirm that patients are willing to participate in this study and comply with research-related requirements.
Exclusion Criteria:
- Metastasis/recurrence occurs within 6 months of adjuvant chemotherapy;
- controlled high blood pressure, systolic blood pressure ≥150mmHg or diastolic blood pressure ≥100mmHg;
- urine routine test with urinary protein more than ++, or 24 hour urinary protein more than 1.0 g;
- abnormal coagulation function (INR > 1.5 or prothrombin time (PT) > ULN+4 seconds or APTT >1.5 times the ULN);
- Pregnant or lactating woman;
- Symptomatic brain parenchymal and/or pia mater metastases without treatment and control;
- Patients with Other malignant tumors in the past 5 years, except for fully treated cervical carcinoma in situ, cutaneous squamous cell carcinoma or well-controlled localized basal cell skin cancer;
- Mental illness or other condition that affects patient compliance;
- serious and uncontrollable systemic diseases (eg clinically significant cardiovascular disease, lung or metabolic disease, arteriovenous thrombosis, etc.) happened recently;
- Can not take or absorb oral drugs;
- Receiving any other testing drugs, or participating in other clinical trial 30 days before being enrolled in this trial;
- The patient has previously received treatment with an anti-angiogenic drug (whether adjuvant or palliative);
- Known or suspected to be allergic to any research drug or excipient;
- Any other researcher believes that it is not appropriate to participate in this test.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Apatinib + Capecitabine
Apatinib 425mg d1-21+ capecitabine 1000mg/m2 bid d1-14, q21d
|
apatinib 425mg qd po
capecitabine 1000mg/m2 bid d1-d14
|
ACTIVE_COMPARATOR: Capecitabine
capecitabine 1000mg/m2 bid d1-14, q21d
|
capecitabine 1000mg/m2 bid d1-d14
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
progression-free survival
Time Frame: up to 6 months
|
Time from randomization to disease progression or death for any cause
|
up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
overall survival
Time Frame: up to 6 months
|
Time from randomization to death for any cause
|
up to 6 months
|
tine to progress
Time Frame: up to 6 months
|
Time from randomization to disease progression
|
up to 6 months
|
Safety: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: up to 6 months
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
|
up to 6 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LB
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Triple-negative Breast Cancer
-
Peregrine PharmaceuticalsWithdrawnBreast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Triple-Negative Breast Cancer | Triple-Negative Breast Neoplasm | ER-Negative PR-Negative HER2-Negative Breast Neoplasms | ER-Negative PR-Negative HER2-Negative Breast Cancer
-
Swiss Group for Clinical Cancer ResearchNot yet recruitingTriple-negative Breast Cancer | TNBC - Triple-Negative Breast CancerSwitzerland
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH); MedImmune...TerminatedTriple Negative Breast Cancer | Triple Negative Breast Neoplasms | TNBC - Triple-Negative Breast Cancer | Triple-negative Breast CarcinomaUnited States
-
AkesoRecruitingMetastatic Triple-negative Breast Cancer | Locally Advanced Triple-negative Breast CancerChina
-
G1 Therapeutics, Inc.TerminatedBreast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast NeoplasmsUnited States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
Fudan UniversityNot yet recruitingTriple-negative Breast Cancer
-
Fudan UniversityRecruitingTriple-Negative Breast CancerChina
-
Fudan UniversityRecruiting
-
Fudan UniversityRecruiting
Clinical Trials on Apatinib
-
Elevar TherapeuticsCompletedAdenoid Cystic CarcinomaUnited States, Korea, Republic of
-
Shanghai Jiao Tong University Affiliated Sixth...UnknownSoft Tissue Sarcoma
-
Tianjin Medical University Cancer Institute and...Unknown
-
Peking University Cancer Hospital & InstituteRecruiting
-
Wuhan Union Hospital, ChinaWithdrawnColorectal Cancer | Chemotherapy | Angiogenesis
-
Tianjin Medical University Second HospitalJiangsu HengRui Medicine Co., Ltd.Unknown
-
Lei LiCompletedChemotherapy | Recurrent Cervical Carcinoma | Apatinib | Targeted Therapy | Persistent Advanced Cervical Carcinoma | Vascular Endothelial Growth Factor 2 InhibitorChina
-
The First Affiliated Hospital of Zhengzhou UniversityRecruitingEsophageal Cancer by AJCC V8 StageChina
-
Peking UniversityJiangsu HengRui Medicine Co., Ltd.Recruiting